文献速递皮肤肿瘤银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

无补骨脂素紫外线光疗后皮肤癌发病率和特征:回顾性队列研究

Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study.
PubMed 文献 · J Am Acad Dermatol · 2023-12-07

该回顾性队列研究纳入1977-2018年教学医院光疗中心3506例接受宽谱UVB、窄谱UVB和/或UVAB治疗的患者,平均随访7.3年。结果显示,基于肿瘤的皮肤癌年龄标准化发病率与一般人群相比无显著差异,未发现UVB累积剂量与皮肤癌之间的剂量-反应关系,结论为光疗未增加黑色素瘤和角质形成细胞癌风险。

要点

  • 无补骨脂素光疗未增加黑色素瘤和角质形成细胞癌风险。
  • 皮肤癌年龄标准化发病率与一般人群相比无显著差异。
  • 未观察到UVB累积剂量与皮肤癌之间的剂量-反应关系。

核心结论

  • 无补骨脂素紫外线光疗未增加黑色素瘤和角质形成细胞癌风险。

研究设计与样本

  • 回顾性队列研究,纳入1977-2018年教学医院光疗中心3506例接受宽谱UVB、窄谱UVB和/或UVAB治疗的患者,平均随访7.3年。

主要发现

  • 共79例患者发生170例皮肤癌(17例黑色素瘤、33例鳞状细胞癌、120例基底细胞癌)。
  • 基于患者的皮肤癌年龄标准化发病率为149(95%CI:112-187)/100,000人年。
  • 基于肿瘤的皮肤癌年龄标准化发病率为264(95%CI:219-309)/100,000人年。
  • 基于肿瘤的黑色素瘤、鳞状细胞癌和基底细胞癌年龄标准化发病率与一般人群相比无显著差异。
  • 银屑病或湿疹患者及使用免疫抑制剂患者中未见显著差异,未观察到UVB累积剂量与皮肤癌的剂量-反应 correlation。

临床怎么用

  • 临床可参考本研究表明无补骨脂素紫外线光疗未增加皮肤癌风险,但需结合患者个体情况评估。

局限性

  • 治疗和随访持续时间可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoralen + ultraviolet-A (PUVA) is associated with photocarcinogenesis. However, carcinogenic risk with other ultraviolet phototherapies remains unclear. OBJECTIVE: Evaluate whether phototherapy without psoralens increases skin cancer risk. METHODS: Retrospective cohort study of patients treated at a teaching-hospital phototherapy center (1977-2018). Skin cancer records were validated against pathology reports. Age-standardized incidence rates (ASIRs) of skin cancer were evaluated for gender, skin phototype, diagnosis, ultraviolet modality, anatomical site; and compared to provincial population incidence rates (2003). RESULTS: In total, 3506 patients treated with broadband-ultraviolet-B, narrowband-UVB and/or combined UVAB were assessed with a mean follow-up of 7.3 years. Majority of patients had psoriasis (60.9%) or eczema (26.4%). Median number of treatments was 43 (1-3598). Overall, 170 skin cancers (17 melanoma, 33 squamous cell carcinoma and 120 basal cell carcinoma) occurred in 79 patients. Patient-based and tumor-based ASIR of skin cancer was 149 (95% CI: 112-187)/100,000 and 264 (219-309)/100,000 person-years, respectively. There was no significant difference between tumor-based ASIRs for melanoma, squamous cell carcinoma, and basal cell carcinoma compared to the general population; or in phototherapy patients with-psoriasis or eczema; or immunosuppressants. No cumulative dose-response correlation between UVB and skin cancer was seen. LIMITATIONS: Treatment and follow-up duration. CONCLUSION: No increased risk of melanoma and keratinocyte cancer was found with phototherapy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang E, Ahad T, Liu YA, et al. Incidence and profile of skin cancers in patients following ultraviolet phototherapy without psoralens: A retrospective cohort study. J Am Acad Dermatol. 2023. PMID: 38070541. doi:10.1016/j.jaad.2023.11.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。